Novavax, COVID-19 and Influenza vaccine
Novavax’s plans for growth outside of its COVID program have been thrown into chaos after the FDA put the biooharma's flu ...
Analyst Eric Joseph of J.P. Morgan maintained a Sell rating on Novavax (NVAX – Research Report), retaining the price target of $9.00.
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-Mâ„¢ adjuvant, today announced ...
The European Commission authorized Novavax's updated COVID-19 vaccine targeting the JN.1 strain of coronavirus in the region, ...
On Wednesday, major U.S. indices saw gains, with the Dow Jones Industrial Average climbing nearly 0.8% to 43,077.70.